Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
2 other identifiers
interventional
545
1 country
1
Brief Summary
People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2, the virus that causes COVID-19, yet due to stigma, fear of mistreatment, and other factors, PWID are far less likely to be vaccinated compared to other populations. In response, we propose to continue our collaboration with a prominent community based organization serving African American and Latino PWID. Our project will explore baseline hesitancy to vaccinate among PWID, identify barriers to vaccination, and then develop and evaluate messaging designed to increase COVID-19 vaccination among our target population of PWID through a clinical trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable covid19
Started Jun 2022
Longer than P75 for not_applicable covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 9, 2021
CompletedFirst Posted
Study publicly available on registry
June 14, 2021
CompletedStudy Start
First participant enrolled
June 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 27, 2026
CompletedMarch 21, 2025
March 1, 2025
3.4 years
June 9, 2021
March 18, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Vaccination uptake at baseline
Did the participant vaccinate when offered?
baseline
Vaccination uptake at follow-up
Did the participant vaccinate when offered?
up to 6 weeks
Vaccination series completion
Did the participant receive a second vaccine dose to complete the vaccination series?
up to 12 weeks
Secondary Outcomes (4)
SARS-CoV-2 literacy at baseline
baseline
SARS-CoV-2 literacy at follow-up
up to 12 weeks
Secondary
baseline
Secondary
up to 12 weeks
Study Arms (2)
No video condition
EXPERIMENTALParticipants in the no video condition will receive weekly text messages designed to increase vaccination among our sample.
Video text condition
EXPERIMENTALParticipants in the video text condition will receive the text messages designed to increase vaccination among our sample, along with links to iteratively developed intervention videos
Interventions
Eligibility Criteria
You may qualify if:
- Participants must be age 18 years or older, able to provide informed consent, able to read and understand English or Spanish. Participants must report injection drug use in the past 90 days. Participants also must not have previously vaccinated against SARS-CoV-2.
You may not qualify if:
- Pregnant women will be excluded. Likewise, adults unable to consent, individuals who are not yet adults (infants, children, teenagers) and prisoners will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- NDRI-USA, Inc.lead
- New York Harm Reduction Educatorscollaborator
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
OnPoint NYC
New York, New York, 10035, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 9, 2021
First Posted
June 14, 2021
Study Start
June 21, 2022
Primary Completion
November 25, 2025
Study Completion
February 27, 2026
Last Updated
March 21, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share